A team led by US Food and Drug Administration (FDA) researchers studying Medicare claims data during the early Omicron SARS-CoV-2 variant months conclude that a third dose of mRNA COVID-19 vaccine provides significant protection against hospitalization and death compared with two doses but wanes substantially after 4 months.
COVID activity in the United States continues to decline, and seasonal flu markers show no upticks, according to the latest respiratory disease updates today from the US Centers for Disease Control and Prevention.
Recent Comments